NYSE · NXGL
Healthcare · Medical - Instruments & Supplies
$0.20
Up+$0.05 (+33.53%)
Updated Oct 10, 2026, 10:22 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NXGL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
NXGL closed at $0.20 after 21 trading sessions, down 31.19% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $0.156 | $0.2203 | $0.151 | $0.2003 | 10.5M |
| Oct 8, 2026 | $0.15 | $0.18 | $0.15 | $0.15 | 1.35M |
| Oct 7, 2026 | $0.17 | $0.1896 | $0.1622 | $0.1772 | 637.48K |
| Oct 6, 2026 | $0.17 | $0.1737 | $0.1651 | $0.1729 | 321.07K |
| Oct 5, 2026 | $0.17 | $0.1727 | $0.1641 | $0.17 | 291.32K |
| Oct 2, 2026 | $0.174 | $0.174 | $0.163 | $0.174 | 222.91K |
| Oct 1, 2026 | $0.177 | $0.1785 | $0.1643 | $0.1785 | 310.95K |
| Sep 30, 2026 | $0.173 | $0.1839 | $0.1663 | $0.1728 | 329.68K |
| Sep 29, 2026 | $0.1814 | $0.1814 | $0.1581 | $0.176 | 300.07K |
| Sep 28, 2026 | $0.179 | $0.1892 | $0.174 | $0.178 | 767.8K |
| Sep 25, 2026 | $0.239 | $0.239 | $0.156 | $0.174 | 3.67M |
| Sep 24, 2026 | $0.27 | $0.2796 | $0.25 | $0.262 | 334.03K |
| Sep 23, 2026 | $0.2595 | $0.2699 | $0.2517 | $0.2682 | 117.45K |
| Sep 22, 2026 | $0.2636 | $0.2757 | $0.261 | $0.2748 | 25.41K |
| Sep 21, 2026 | $0.2707 | $0.2707 | $0.2528 | $0.2649 | 76.08K |
| Sep 18, 2026 | $0.2512 | $0.2838 | $0.2512 | $0.2658 | 151.53K |
| Sep 17, 2026 | $0.256 | $0.2797 | $0.2464 | $0.259 | 285.41K |
| Sep 16, 2026 | $0.272 | $0.2785 | $0.24 | $0.2482 | 444.15K |
| Sep 15, 2026 | $0.277 | $0.2909 | $0.277 | $0.2811 | 69.01K |
| Sep 14, 2026 | $0.286 | $0.29 | $0.2749 | $0.2807 | 66.42K |
| Sep 11, 2026 | $0.286 | $0.2952 | $0.2809 | $0.2911 | 90.05K |
The latest Smart Investors Daily articles mentioning NXGL.
Company
Market Activity
Research & News
NXGL research
Company profile and research snapshot.
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Maxim Group | Hold | — |
| Mar 12, 2026 | Maxim Group | Buy | — |
| Feb 25, 2022 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 7, 2026
Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98% to $6.64.
Benzinga · Sep 25, 2026
Gainers Firefly Neuroscience (NASDAQ:AIFF) shares increased by 33.2% to $1.58 during Friday's regular session. The company's market cap stands at $18.6 million. Apimeds Pharmaceuticals (AMEX:APUS) shares moved
Benzinga · Sep 25, 2026
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares rose 23.4% to $6.07 during Friday's pre-market session. The market value of their outstanding shares is at $7.4 million. Firefly Neuroscience (NASDAQ:AIFF) shares
Benzinga · Aug 24, 2026
Maxim Group analyst Naz Rahman downgrades NexGel (NASDAQ:NXGL) from Buy to Hold.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NXGL.
